Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.72, moving 3.13% from the previous trading session.
RXRX - Recursion Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$5.50
DETAILS
HIGH:
$5.50
LOW:
$5.50
MEDIAN:
$5.50
CONSENSUS:
$5.50
UPSIDE:
54.49%
Stock News
3 Cancer Stocks to Watch as Oncology Innovation Accelerates
Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Two stocks that have fallen out of favor and one hot stock that was one of Thursday's biggest losers were on the Ark Invest founder's shopping list.
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?
Dyne Therapeutics is advancing a clinical-stage platform specifically targeting genetically driven neuromuscular diseases. Recursion Pharmaceuticals utilizes an artificial intelligence OS to accelerate drug discovery across several therapeutic areas.
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?
Moderna is evolving from a COVID-19 vaccine specialist into a multi-product firm with major oncology and rare disease partnerships. Recursion Pharmaceuticals is leveraging artificial intelligence and massive biological datasets to accelerate drug discovery via high-tech collaborations.
AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity
Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from Silicon Valley. Biotechnology has spent decades producing breakthrough medicines, yet drug development has remained painfully slow, often taking 10 to 15 years while roughly 90% of candidates never reach approval. AI is beginning to change that equation. By... AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?
2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying
Recursion Pharmaceuticals' approach to drug discovery could advance the industry. Fiverr is implementing a strategy shift that may help it bounce back from recent headwinds.
Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note
Recursion Pharmaceuticals (RXRX) closed at $3.23 in the latest trading session, marking a +2.22% move from the prior day.
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $3.18, representing a -3.34% change from its previous close.
Recursion Pharmaceuticals: Short-Trade Crowded But Near-Term Squeeze Not Guaranteed
Recursion Pharmaceuticals, Inc. is advancing REC-1245, an RBM39 degrader, in the DHALIA trial in solid tumors, with Q1'26 earnings noting no dose-limiting toxicities so far. Initial DHALIA trial data are based on a small cohort of 16 patients, with the drug only now reaching relevant dose levels for anti-tumor activity, limiting conclusions. A H2 '26 update from DHALIA could confirm anti-tumor activity of REC-1245, but might not have enough additional data to go beyond that.
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.06, moving 5.12% from the previous trading session.
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Recursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue?
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock?
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?
Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.
Recursion to Participate in Upcoming Investor Conferences
Salt Lake City, UT, June 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in an upcoming investor conference: Goldman Sachs 47th Annual Global Healthcare Conference — Tuesday, June 9, 2026 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com . About Recursion Recursion (NASDAQ: RXRX) is a clinical-stage TechBio company decoding biology to radically improve lives.
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
Salt Lake City, UT, May 29, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on May 26, 2026, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 2,991,840 shares of its class A common stock in the aggregate to 33 new employees under Recursion's 2024 Inducement Equity Incentive Plan (the “2024 Plan”). Each award was granted as an inducement material to the employee's commencement of employment with Recursion, or a subsidiary of Recursion, pursuant to Nasdaq Listing Rule 5635(c)(4).
Altitude Lab Portfolio Companies Surpass $205 Million in Funding, Marking a New Era for Early-Stage Biotechs in Salt Lake City
Altitude Lab portfolio companies surpass $205M in funding as startups advance clinical trials, sign global pharma deals, and reshape early-stage biotech.
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
3 Stocks Poised to Disrupt the Healthcare Market by 2030
The old healthcare model is breaking down.
Price Targets
Recursion Pharmaceuticals price target raised to $5.50 from $5 at Morgan Stanley
$5.50
(was $3.08)
Morgan Stanley
JPMorgan Upgrades Recursion Pharmaceuticals (RXRX ) to Overweight
$11.00
(was $4.20)
UBS
JPMorgan Upgrades Recursion Pharmaceuticals (RXRX ) to Overweight
$11.00
(was $4.20)
Morgan Stanley
Recursion Pharmaceuticals price target lowered to $6 from $7 at Leerink
$6.00
(was $7.51)
Leerink Partners
Recursion Pharmaceuticals (RXRX) PT Lowered to $11 at Needham
$11.00
(was $6.10)
Gil Blum
·
Needham
KeyBanc Reiterates Overweight Rating on Recursion Pharmaceuticals (RXRX )
$12.00
(was $6.07)
Scott Schoenhaus
·
KeyBanc
Recursion Pharmaceuticals price target lowered to $6 from $8 at Jefferies
$6.00
(was $6.02)
Dennis Ding
·
Jefferies
KeyBanc Reiterates Overweight Rating on Recursion Pharmaceuticals (RXRX )
$16.00
(was $8.76)
Scott Schoenhaus
·
KeyBanc